Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | — |
The patient took first dose of VIVOTIF and had about 35 hours of fever; Case reference number US-BN-2025-000119 is a spontaneous case initially received from consumer via Communications (reference number: USBAV25-0094) on 13-Jan-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown) at unknown dose, unknown route or site of administration, for unknown indication. On an unspecified date, unknown of time after taking the VIviotif vaccine, the patient had about 35 hours of fever. At the time of the initial report, it was unknown if the patient recovered from the event of 'fever'. The reporter assessed the event of 'fever' as non-serious. The reporter did not provide causality assessment for the event of 'fever'. No further information was provided.; Reporter's Comments: A male patient of unspecified age experienced a non-serious event of fever on an unspecified date, an unknown of time after the patient took the first dose of Vivotif for unknown indication. Pyrexia is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age experienced a non-serious event of fever on an unspecified date, an unknown of time after the patient took the first dose of Vivotif for unknown indication. Pyrexia is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.
Comments: None.